2025-01-22 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Review

**1. Performance Comparison and Divergence:**

Colgate-Palmolive (CL) is a consumer staples company that manufactures and sells a wide range of household and personal care products.

Over the given period, CL's cumulative return (34.84%) significantly underperformed the S&P 500 (VOO) with a cumulative return of 120.36%.  The difference is -85.5%, indicating substantial underperformance relative to the broader market.  The provided relative divergence of 0.0% suggests this underperformance falls at the lowest end of the historical range observed in the data.


**Alpha and Beta Analysis:**

The provided alpha and beta values show inconsistent performance against the market.  While alpha is consistently positive, suggesting some degree of outperformance, the beta is consistently high (around 0.2), showing a relatively low sensitivity to market movements.  The high CAGR values in some periods do not consistently reflect the overall cumulative underperformance compared to the S&P 500.  Note that the provided data is not sufficient to definitively characterize the stock's performance.  A longer data series is essential for drawing robust conclusions.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 12.0% | 12.6% | -15.0% | 0.2 | 72.0 |
| 2016-2018  | -7.0% | 13.9% | -22.0% | 0.2 | 72.0 |
| 2017-2019  | 9.0% | 13.9% | -23.0% | 0.2 | 72.0 |
| 2018-2020  | 21.0% | 21.5% | -13.0% | 0.2 | 72.0 |
| 2019-2021  | 41.0% | 21.5% | -39.0% | 0.2 | 72.0 |
| 2020-2022  | 16.0% | 21.5% | 9.0% | 0.2 | 72.0 |
| 2021-2023  | -6.0% | 16.2% | -30.0% | 0.2 | 72.0 |
| 2022-2024  | 10.0% | 16.2% | -12.0% | 0.2 | 72.0 |
| 2023-2025  | 14.0% | 18.4% | -58.0% | 0.2 | 72.0 |


**2. Recent Price Movement:**

* **Closing Price:** $88.23
* **5-day Moving Average:** $88.20
* **20-day Moving Average:** $89.63
* **60-day Moving Average:** $92.64

The stock price is currently trading below its 5, 20, and 60-day moving averages, suggesting a downtrend.  The recent price change of $0.045 is minimal and does not indicate significant upward or downward momentum.

**3. Technical Indicators and Expected Return:**

* **RSI:** 29.23 (Suggests oversold conditions)
* **PPO:** 0.08 (Indicates a slightly bullish momentum)
* **20-day Relative Divergence:** -4.8% (Short-term downward trend)
* **Expected Return:** -4804.6% (This extremely negative value requires further investigation and clarification as it's likely an error or misinterpretation of the data.)


**4. Recent Earnings Analysis:**

The recent earnings data show relatively stable revenue around $5 billion, with slight fluctuations.  EPS has also remained relatively consistent but shows a slight downward trend in the recent quarter.

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2024-10-25 | 0.9  | $5.03 B       |
| 2024-07-26 | 0.89 | $5.06 B       |
| 2024-04-26 | 0.83 | $5.07 B       |
| 2023-10-27 | 0.86 | $4.92 B       |
| 2024-10-25 | 0.86 | $4.92 B       |


**5. Financial Information:**

Revenue remains relatively stable, while profit margins show a slight downward trend.  The equity and ROE data are highly volatile and require further analysis to understand the underlying factors.  The negative equity and extremely high negative ROE in 2023-09-30 warrant a detailed examination.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $5.03B | 61.08% |
| 2024-06-30 | $5.06B | 60.62% |
| 2024-03-31 | $5.07B | 60.00% |
| 2023-12-31 | $4.95B | 59.60% |
| 2023-09-30 | $4.92B | 58.54% |


**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-09-30 | $0.43B | 169.43% |
| 2024-06-30 | $0.12B | 594.31% |
| 2024-03-31 | $0.23B | 296.96% |
| 2023-12-31 | $0.61B | 117.90% |
| 2023-09-30 | $-0.01B | -7866.67% |



**7. Overall Analysis:**

Colgate-Palmolive's performance has significantly lagged the S&P 500 over the observed period. While the company shows relatively stable revenue and earnings, the substantial underperformance relative to the market and volatile financial metrics raise concerns. The extremely high negative expected return needs clarification. The highly volatile ROE and negative equity in a single quarter necessitate further investigation into the underlying financial health of the company.  A more thorough analysis, including consideration of industry trends and macroeconomic factors, is needed to make a well-informed investment decision.  The provided data suggests a potential need for further due diligence before making any investment decisions.


**8. Disclaimer:** This analysis is based on the limited data provided.  It is not financial advice and should not be used as the sole basis for investment decisions.  Consult with a qualified financial advisor before making any investment choices.
